Pfizer-Drug PF-08634404 for hepatocellular carcinoma (C6461013) - Clinical Trial
Who Can Participate in the Study?
Age Group
Adults
Study Details
Full Title
[C6461013] An Interventional Open-label Phase 1b/2 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Efficacy of PF-08634404 as Monotherapy and Combination Therapy in Adult Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma
Principal Investigator
Michael A. Morse, MD, FACP, MHS
Medical Oncologist
Protocol Number
IRB:
PRO00119394
NCT:
NCT07227012
Phase
Phase I/II
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment